Indications for MYCAMINE:
Treatment of candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses, and esophageal candidiasis in patients aged ≥4 months. Treatment of candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses without meningoencephalitis and/or ocular dissemination in children aged <4 months. Prophylaxis of Candida infections in patients aged ≥4 months undergoing hematopoietic stem cell transplantation (HSCT).
Give by slow IV infusion over 1hr. Candidemia, acute disseminated, peritonitis, abscesses: 100mg/day (usual range 10–47 days). Esophageal: 150mg/day (usual range 10–30 days). Prophylaxis in HSCT: 50mg/day (usual range 6–51 days).
See full labeling. Give by slow IV infusion over 1hr. Candidemia, acute disseminated, peritonitis, abscesses: <4months (without meningoencephalitis and/or ocular dissemination only): 4mg/kg once daily; ≥4months: 2mg/kg once daily; max 100mg/day. Esophageal: <4months: not established. ≥4months (≤30kg): 3mg/kg once daily; (>30kg): 2.5mg/kg once daily; max: 150mg/day. Prophylaxis in HSCT: <4months: not established. ≥4months: 1mg/kg once daily; max 50mg/day.
Monitor for evidence of worsening hepatic or renal function, hemolysis or hemolytic anemia. Pregnancy. Nursing mothers.
Glucan synthesis inhibitor (echinocandin).
Potentiates sirolimus, itraconazole, nifedipine; monitor and reduce doses.
Diarrhea, nausea, vomiting, abdominal pain, pyrexia, thrombocytopenia, neutropenia, headache; inj site/infusion reactions, hematological effects, abnormal liver function tests, acute renal failure, hypersensitivity reactions (discontinue if occur). Also in infants: sepsis, acidosis, anemia, oxygen saturation decreased, hypokalemia.
Generic Drug Availability: